Journals / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 6

Risk Factors for Vitamin D Deficiency in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Pages
508–518
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The relationship between body mass index, winter season, exposure to immunomodulators, and vitamin D deficiency remains unclear.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: To identify risk factors for hypovitaminosis D in inflammatory bowel disease and conduct a comprehensive systematic review with meta-analysis to quantify the impact on vitamin D deficiency.
📊
Key Findings & Data:Studies were included if the odds ratios (OR) and 95% CI of each risk factor were reported or could be calculated.
💡
Conclusion & Impact:The relationship between body mass index, winter season, exposure to immunomodulators, and vitamin D deficiency remains unclear.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: To identify risk factors for hypovitaminosis D in inflammatory bowel disease and conduct a comprehensive systematic review with meta-analysis to quantify the impact on vitamin D deficiency. Methods: We conducted a literature search of studies through PubMed, Embase, Cochrane Library, and Web of Science. In addition, relevant articles were searched manually. Studies were included if the odds ratios (OR) and 95% CI of each risk factor were reported or could be calculated. We will use the fixed-effects or random-effects model to estimate the pooled effect. Results: Out of 1018 articles, 25 eligible studies were identified, including 5826 participants. The risk factors associated with hypovitaminosis D were non-Caucasian (OR: 3.79, 95% CI: 2.68-5.34), Crohn’s disease (OR: 1.38, 95% CI: 1.21-1.56), disease activity (OR: 1.85, 95% CI: 1.61-2.13), inflammatory bowel disease-related surgery (OR: 1.61, 95% CI: 1.38-1.89), exposure to steroid (OR: 1.61, 95% CI: 1.28-2.03), and biologics (OR: 1.78, 95% CI: 1.48-2.14). In 30 ng/mL and adjusted OR subgroup, male (OR: 1.84, 95% CI: 1.47-2.31) and winter season (OR: 2.49, 95% CI: 1.69-3.67) also were risk factors, respectively. 5-aminosalicylic acid (OR: 1.10, 95% CI: 0.74-1.63) and smoking (OR: 1.19, 95% CI: 0.98-1.45) were unrelated to vitamin D deficiency. Conclusions: For vitamin D deficiency in inflammatory bowel disease, non-Caucasian, Crohn’s disease, disease activity, surgery, exposure to steroid and biologics, males are risk factors, while 5-aminosalicylic acid and smoking are not. The relationship between body mass index, winter season, exposure to immunomodulators, and vitamin D deficiency remains unclear.

🔖

Cite This Article

SHİ, S., FENG, J., ZHOU, L., Lİ, Y., SHİ, H. (2021). Risk Factors for Vitamin D Deficiency in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 6, 508–518. https://ajindex.com/articles/408848

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390(10114):2769- 2778. [CrossRef] 2. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. [CrossRef] 3. Ananthakrishnan AN, Bernstein CN, Iliopoulos D et al. Environmental triggers in IBD: A review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15(1):39-49. [CrossRef] 4. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: An integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(12):739-749. [CrossRef] 5. Nielsen OH, Rejnmark L, Moss AC. Role of vitamin D in the natural history of inflammatory bowel disease. J Crohns Colitis. 2018;12(6):742-752. [CrossRef] 6. Alhassan Mohammed HA, Mirshafiey A, Vahedi H et al. Immunoregulation of inflammatory and inhibitory cytokines by vitamin D3 in patients with inflammatory bowel diseases. Scand J Immunol. 2017;85(6):386-394 [CrossRef] 7. Li J, Zuo L, Tian Y et al. Spontaneous colitis in IL-10-deficient mice was ameliorated via inhibiting glutaminase1. J Cell Mol Med. 2019;23(8):5632-5641. [CrossRef] 8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-1657. [CrossRef] 9. Ghishan FK, Kiela PR. VitaminS and minerals in inflammatory bowel disease. Gastroenterol Clin North Am. 2017;46(4):797-808. [CrossRef] 10. Piovani D, Danese S, Peyrin-Biroulet L et al. Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology. 2019;157(3):647-659.e4. [CrossRef] 11. Del Pinto RD, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association Between inflammatory bowel disease and vitamin D deficiency: A systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(11):2708-2717. [CrossRef] 12. Huang J, Chen T, Liu Y et al. How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-α hydroxylase (CYP27B1)? Turk J Gastroenterol. 2019;30(2):132-138. [CrossRef] 13. Basson AR, Swart R, Jordaan E, Mikatako M, Watermeyer G. Vitamin D deficiency increases the risk for moderate to severe disease activity in Crohn’s disease patients in South Africa, measured by the Harvey Bradshaw index. J Am Coll Nutr. 2015;35:1-12. 1